Detalles de la búsqueda
1.
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699.
J Pharmacol Exp Ther
; 355(3): 506-15, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26442523
2.
Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
Mol Pharm
; 11(2): 477-85, 2014 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24380373
3.
Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats.
Xenobiotica
; 44(12): 1108-16, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947446
4.
Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
Bioorg Med Chem Lett
; 23(10): 3028-33, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23578688
5.
Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
Xenobiotica
; 42(11): 1058-68, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22574883
6.
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Bioorg Med Chem Lett
; 21(15): 4633-7, 2011 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21705217
7.
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
J Med Chem
; 51(1): 4-16, 2008 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-18072718
8.
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Cancer Chemother Pharmacol
; 61(3): 365-76, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17429625
9.
Benzothiazole based inhibitors of p38alpha MAP kinase.
Bioorg Med Chem Lett
; 18(6): 1874-9, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18296051
10.
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
Bioorg Med Chem Lett
; 18(6): 1762-7, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18313298
11.
Development and validation of a preclinical food effect model.
J Pharm Sci
; 96(2): 459-72, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17075867
12.
In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions.
Curr Drug Metab
; 7(7): 687-704, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17073574
13.
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Cancer Chemother Pharmacol
; 58(1): 73-85, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16228206
14.
Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.
AAPS J
; 18(6): 1391-1405, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27495117
15.
P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
Cancer Chemother Pharmacol
; 55(2): 110-6, 2005 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-15338193
16.
Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Cancer Chemother Pharmacol
; 56(2): 145-53, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15830240
17.
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor.
J Med Chem
; 58(19): 7775-84, 2015 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26359680
18.
Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Methods Mol Biol
; 596: 385-403, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-19949933
19.
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
J Med Chem
; 53(18): 6629-39, 2010 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-20804198
20.
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Cancer Chemother Pharmacol
; 65(1): 55-66, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19396600